First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study-Reference-Cited by-同舟云学术

First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study

Published:2017-10-27 Issue:12 Volume:33 Page:2137-2143
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Tang Derek H.¹,Li Nanxin²,Du Ella X.³,Peeples Miranda²,Chu Lihao³,Xie Jipan³,Barghout Victoria⁴

Affiliation:

1. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

2. Analysis Group, Inc., Boston, MA, USA;

3. Analysis Group, Inc., Los Angeles, CA, USA;

4. VEB HealthCare LLC, Morristown, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1390447

Reference35 articles.

1. International Agency for Research on Cancer–Cancer Research UK. World cancer factsheet; 2014. Available at: http://publications.cancerresearchuk.org/downloads/Product/CS_REPORT_WORLD.pdf

2. Extending Survival with Chemotherapy in Metastatic Breast Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study;Frontiers in Oncology;2022-07-26

2. Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer;Current Medical Research and Opinion;2018-09-20